<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937401</url>
  </required_header>
  <id_info>
    <org_study_id>T366/2017</org_study_id>
    <nct_id>NCT03937401</nct_id>
  </id_info>
  <brief_title>Oxytocin in MRI-HIFU</brief_title>
  <official_title>Use of Oxytocin in MRI-HIFU Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing
      MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will
      be analysed by patient reported symptom questionnaires and imaging data.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NPV</measure>
    <time_frame>up to one year</time_frame>
    <description>non perfused volume (percentage of fibroid destroyed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of MRI-HIFU</measure>
    <time_frame>up to one year</time_frame>
    <description>duration of MRI-HIFU treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UFS-Qol</measure>
    <time_frame>12 months after HIFU treatment</time_frame>
    <description>Uterine fibroid symptom severity and quality of life (patient quality of life questionnaire)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fibroid</condition>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Patients treated with oxytocin during MRI-HIFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin infusion during MRI-HIFU treatment</description>
    <arm_group_label>Patients treated with oxytocin during MRI-HIFU</arm_group_label>
    <other_name>MRI-HIFU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing MRI-HIFU -treatment

          -  Patients assessed for suitability to MRI-HIFU treatment

          -  willingness to participate in trial

        Exclusion Criteria:

          -  Known allergy to Syntocinon/oxytocin

          -  Elevated blood pressure

          -  ischemic heart disease

          -  Long QT- interval
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>MRI-HIFU</keyword>
  <keyword>fibroid</keyword>
  <keyword>adenomyosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

